Рroblems and ways to correct anticoagulant therapy in patients with coronavirus infection

Abstract

Patients with COVID 19 have a hypercoagulable state, which increases the risk of thrombosis and thromboembolic complications. This condition is also called COVID 19 associated coagulopathy, which manifests as increased fibrinogen and D-dimer levels, prolongation of aPTT (Activated Partial Thromboplastin Time) and PT (Prothrombin time), changes in platelet levels in the early stage of the disease. This article discusses issues and problems of rational anticoagulant therapy in patients with coronavirus infection